Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Hilton Hotels Corporation Common Stock — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.82 (market cap $4.49B), while Hilton Hotels Corporation Common Stock trades at $334.47 (market cap $77.66B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 17.3× ACADIA Pharmaceuticals Inc.'s market cap, and Hilton Hotels Corporation Common Stock pays a 0.18% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | HLT | |
|---|---|---|
Market Cap | $4.49B | $77.66B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $350.22 |
52-Week Low | $20.06 | $256.75 |
Enterprise Value | $3.69B | $90.15B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Hilton Worldwide (HLT) trades at $341.12, up 0.89% with strong technical momentum as price approaches resistance at $342. The stock shows consistent earnings beats with Q1 2026 EPS of $2.01 exceeding expectations of $1.98, while revenue growth continues from $12.04B in 2025 to projected $12.3B in 2026. Analyst consensus remains bullish with 55% buy ratings and a $342.11 price target closely aligned with current levels.
The outlook remains positive given Hilton's market leadership and sustained travel demand, though elevated debt levels and valuation multiples present risks. With technical indicators showing bullish momentum and strong institutional support, the stock appears positioned for continued growth, though investors should monitor debt management and competitive pressures in the hospitality sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
